生产力
制药工业
业务
经济
医学
药理学
宏观经济学
出处
期刊:The MIT Press eBooks
[The MIT Press]
日期:2007-01-01
被引量:41
标识
DOI:10.7551/mitpress/3788.003.0002
摘要
Rising R&D expenditures and falling counts of new drug approvals since 1996 have lead many observers to conclude that there has been a sharp decline in research productivity in the pharmaceutical industry over the past decade. A close look at the underlying data, however, suggests that these trends are greatly exaggerated: properly measured, research output is unlikely to have fallen as much as these figures imply, while trends in R&D expenditure are seriously overstated by failing to account for inflation in R&D input costs. Some of the increase in R&D investment is a necessary, indeed welcome, response to new technological opportunities and can be expected to deliver a handsome return of innovative drugs in future years. The rising cost per new drug approved is nonetheless a serious cause for concern, particularly where this is driven by transactions costs and other inefficiencies in the market for basic research, and by late-stage abandonment of drug development projects on purely economic grounds. Pol...
科研通智能强力驱动
Strongly Powered by AbleSci AI